1. Market Research
  2. > Transportation
  3. > Logistics and Freight Market Trends
  4. > Global Genitourinary Partnering Terms and Agreements

Global Genitourinary Partnering Terms and Agreements

  • July 2015
  • -
  • Currentpartnering
  • -
  • 511 pages

The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service.

The Genitourinary Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the genitourinary partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter genitourinary partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors genitourinary technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 1,000 links to online copies of actual genitourinary deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of genitourinary dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in genitourinary dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading genitourinary deals since 2010. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of genitourinary deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides comprehensive access to all genitourinary deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all genitourinary partnering deals signed and announced since 2010. The chapter is organized by specific genitourinary therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all genitourinary partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in genitourinary partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of genitourinary technologies and products.
Genitourinary Partnering Terms and Agreements provides the reader with the following key benefits:

• In-depth understanding of genitourinary deal trends since 2010
• Access genitourinary deal headline, upfront, milestone and royalty data
• Research hundreds of actual contracts between genitourinary partner companies
• Comprehensive access to over 1,000 links to actual genitourinary deals entered into by the world’s biopharma companies
• Indepth review of genitourinary deals entered into by the leading fifty bigpharma companies
• Benchmark the key deal terms companies have agreed in previous deals
• Identify key terms under which companies partner genitourinary opportunities
• Uncover companies actively partnering genitourinary opportunities

Table Of Contents

Global Genitourinary Partnering Terms and Agreements
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in genitourinary dealmaking

2.1. Introduction
2.2. Genitourinary partnering over the years
2.3. Big pharma genitourinary dealmaking activity
2.4. Big biotech genitourinary dealmaking activity
2.5. Most active in genitourinary partnering
2.6. Genitourinary partnering by deal type
2.7. Genitourinary partnering by industry sector
2.8. Genitourinary partnering by stage of development
2.9. Genitourinary partnering by technology type
2.10. Genitourinary partnering by genitourinary indication
2.11. Average deal terms for genitourinary
2.11.1 Genitourinary headline values
2.11.2 Genitourinary upfront payments
2.11.3 Genitourinary milestone payments
2.11.4 Genitourinary royalty rates

Chapter 3 - Leading genitourinary deals

3.1. Introduction
3.2. Top genitourinary deals by value

Chapter 4 - Big pharma genitourinary deals

4.1. Introduction
4.2. How to use big pharma partnering deals
4.3. Big pharma genitourinary partnering company profiles
Abbott
Actavis
Allergan
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Fresenius
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson and Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck and Co
Merck KGaA
Mitsubishi Tanabe
Mylan
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Ranbaxy Laboratories
Roche
Sanofi
Servier
Shionogi
Shire
Stada
Takeda
Teva
UCB
Valeant
Warner Chilcott

Chapter 5 - Big biotech genitourinary deals

5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech genitourinary partnering company profiles
3SBio
Acorda Therapeutics
Actelion
Alexion Pharmaceuticals
Alkermes
AMAG Pharmaceuticals
Amgen
Anika Therapeutics
Array Biopharma
Bavarian Nordic
Biocon
Biogen Idec
BioMarin Pharmaceuticals
Cangene
Celgene
CSL
Cubist
Dendreon
Elan
Emergent BioSolutions
Enzo Biochem
Galapagos
Genmab
Gilead Sciences
Grifols
Ipsen
Isis Pharmaceuticals
LFB Group
Medivation
Morphosys
Nektar Therapeutics
Novo Nordisk
NPS Pharmaceuticals
Onyx Pharmaceuticals
Optimer
PDL BioPharma
Questcor Pharmaceuticals
Regeneron Pharmaceuticals
Roche
SciClone Pharmaceuticals
Seattle Genetics
Shire
Spectrum Pharmaceuticals
Swedish Orphan Biovitrum
The Medicines Company
UCB
United Therapeutics
Vertex Pharmaceuticals
ViroPharma
Zeltia

Chapter 6 - Genitourinary partnering contracts directory

6.1. Introduction
6.2. Genitourinary partnering by company A-Z
6.3. Genitourinary partnering by deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative RandD
Co-market
Contract service
Co-promotion
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Joint venture
Licensing
Litigation
Loan
Manufacturing
Manufacturing - OEM
Marketing
Option
Promotion
Research
Royalty financing
Settlement
Spin out
Sub-license
Supply
Termination
Warranty
6.4. Genitourinary partnering by stage of development
6.5. Genitourinary partnering by technology type

Chapter 7 - Genitourinary dealmaking by therapeutic target

7.1. Introduction
7.2. Deals by therapeutic target

Appendices

Appendix 1 - Directory of genitourinary deals by company A-Z 2010-2015
Appendix 2 - Directory of genitourinary deals by deal type 2010-2015
Appendix 3 - Directory of genitourinary deals by stage of development 2010-2015
Appendix 4 - Directory of genitourinary deals by technology type 2010-2015
Appendix 5 - Partnering resource center
Online partnering
Partnering events
Further reading on dealmaking
Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements

Recent report titles from Current Partnering

Order Form - Therapy Reports

Table of figures

Figure 1: Genitourinary partnering since 2010
Figure 2: Big pharma - top 50 - genitourinary deals 2010 to 2015
Figure 3: Big pharma genitourinary deal frequency - 2010 to 2015
Figure 4: Big biotech - top 50 - genitourinary deals 2010 to 2015
Figure 5: Big biotech genitourinary deal frequency - 2010 to 2015
Figure 6: Active genitourinary dealmaking activity- 2010 to 2015
Figure 7: Genitourinary partnering by deal type since 2010
Figure 8: Genitourinary partnering by industry sector since 2010
Figure 9: Genitourinary partnering by stage of development since 2010
Figure 10: Genitourinary partnering by technology type since 2010
Figure 11: Genitourinary partnering by [] target since 2010
Figure 12: Genitourinary deals with a headline value
Figure 13: Genitourinary deal headline value distribution, US$million - discovery stage
Figure 14: Genitourinary deal headline value distribution, US$million - preclinical stage
Figure 15: Genitourinary deal headline value distribution, US$million - phase I stage
Figure 16: Genitourinary deal headline value distribution, US$million - phase II stage
Figure 17: Genitourinary deal headline value distribution, US$million - phase III stage
Figure 18: Genitourinary deal headline value distribution, US$million - regulatory stage
Figure 19: Genitourinary deal headline value distribution, US$million - marketed stage
Figure 20: Summary median headline value by stage of development, 2010-2015
Figure 21 Genitourinary deals with upfront payment values
Figure 22: Genitourinary deal upfront payment distribution, US$million - discovery stage
Figure 23: Genitourinary deal upfront payment distribution, US$million - preclinical stage
Figure 24: Genitourinary deal upfront payment distribution, US$million - phase I stage
Figure 25: Genitourinary deal upfront payment distribution, US$million - phase II stage
Figure 26: Genitourinary deal upfront payment distribution, US$million - phase III stage
Figure 27: Genitourinary deal upfront payment distribution, US$million - regulatory stage
Figure 28: Genitourinary deal upfront payment distribution, US$million - marketed stage
Figure 29: Summary median upfront payments by stage of development, 2010-2015
Figure 30: Genitourinary deals with milestone payments
Figure 31: Genitourinary deal milestone distribution, US$million - discovery stage
Figure 32: Genitourinary deal milestone distribution, US$million - preclinical stage
Figure 33: Genitourinary deal milestone distribution, US$million - phase I stage
Figure 34: Genitourinary deal milestone distribution, US$million - phase II stage
Figure 35: Genitourinary deal milestone distribution, US$million - phase III stage
Figure 36: Genitourinary deal milestone distribution, US$million - regulatory stage
Figure 37: Genitourinary deal milestone distribution, US$million - marketed stage
Figure 38: Genitourinary deals with royalty rates, %
Figure 39: Genitourinary deal royalty rate distribution, US$million - discovery stage
Figure 40: Genitourinary deal royalty rate distribution, US$million - preclinical stage
Figure 41: Genitourinary deal royalty rate distribution, US$million - phase I stage
Figure 42: Genitourinary deal royalty rate distribution, US$million - phase II stage
Figure 43: Genitourinary deal royalty rate distribution, US$million - phase III stage
Figure 44: Genitourinary deal royalty rate distribution, US$million - regulatory stage
Figure 45: Genitourinary deal royalty rate distribution, US$million - marketed stage
Figure 46: Summary median royalty rate by stage of development, 2010-2015
Figure 47: Top genitourinary deals by value since 2010
Figure 48: Online partnering resources
Figure 49: Forthcoming partnering events

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Future of Logistics

Future of Logistics

  • $ 10000
  • Industry report
  • September 2016
  • by Frost & Sullivan

Unbundling of the Supply Chain The supply chain market is becoming more complex in a time-constrained environment as speed of delivery and user experience emerge as critical factors; in fact, instant and ...

Industrial Labels Market by Type, Material, Industry, Mechanism, Printing Technology, Identification Technology, and Region - Global Forecast to 2021

Industrial Labels Market by Type, Material, Industry, Mechanism, Printing Technology, Identification Technology, and Region - Global Forecast to 2021

  • $ 9000
  • Industry report
  • October 2016
  • by MarketsandMarkets

“Growing demand in the parent industries to propel the market for industrial labels” The global market for industrial labels is projected to grow from USD 43.04 billion in 2016 to reach USD 55.95 ...

Warehouse Management Systems Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

Warehouse Management Systems Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • September 2016
  • by Transparency Market Research

This report aims to provide a comprehensive strategic analysis of the global warehouse management systems market along with revenue and growth forecasts for the period from 2014 to 2024. With advancements ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.